American Academy of Neurology 58th Annual Meeting Scientific Highlights:
"Two studies highlighted advances in treatment of multiple sclerosis (MS). The experimental drug FTY720, derived from a Chinese herb and currently in clinical trials, demonstrated its ability to reduce lesions in the brain, and to reduce the number of relapses patients experience over the course of the year. Another study showed that natalizumab delays disease progression, reduces disability progression, and reduces brain lesions. Natalizumab is an antibody that was withdrawn from the market shortly after it was approved for treatment of MS. It has recently been reapproved by the Food and Drug Administration."